Literature DB >> 30061804

The Prevalence of the Most Important Risk Factors Associated with Cervical Cancer.

Azra Lukac1, Nenad Sulovic2, Sonja Smiljic3, Aleksandra N Ilic4, Orhan Saban5.   

Abstract

INTRODUCTION/ GOALS: The aim of our study was to point out the importance of the risk factors associated with cervical cancer in an asymptomatic population.
METHODOLOGY: The study included 860 patients in the period from January 2017 to January 2018, which covered more than 80% of the targeted population in this municipality over the one year study, according to the National Program for Cervical Cancer Prevention in Montenegro.
RESULTS: The incidence of PAP III results was statistically significantly higher in women between 40 and 45 years of age compared to other age groups (p< 0.001). PAP III was statistically significant high in subjects who had vaginal delivery (p<0.001), and was statistically significantly more frequent in women with more than two children (p = 0.011), while all the subjects with positive PAP results III had children. PAP III results were statistically significantly higher in subjects who had sexual intercourse before the age of 18 (p< 0.001), and were statistically significantly more frequent in subjects who were on oral contraceptives (p< 0.001). PAP III test results also show a significant difference related to cigarette consumption (p< 0.001). PAP III results were significantly more frequent in subjects with grade III vaginal cleanliness compared to grade II vaginal cleanliness (p<0.001).
CONCLUSION: The number of patients with cervical cancer in Montenegro increased in the period from June 2016 to June 2017, compared to previous years, even though the National Program for Cervical Cancer Prevention that aimed to reduce the number of such patients has been in use in Montenegro since 2011.

Entities:  

Keywords:  cervical cancer; pap test

Year:  2018        PMID: 30061804      PMCID: PMC6029895          DOI: 10.5455/msm.2018.30.131-135

Source DB:  PubMed          Journal:  Mater Sociomed        ISSN: 1512-7680


INTRODUCTION

Cervical cancer is still one of the most common malignant diseases in the world, ranked second in its frequency, which is indicative of the pandemic characteristic of this type of cancer, with more than 80% of cases being detected in the developing countries (Montenegro being one of them). According to the data available to the World Health Organization (WHO), about half a million women worldwide develop cervical cancer each year, accounting for 12% of all malignant diseases in women. Every two minutes one women dies from cervical cancer which leads us to conclude that for 230 000 of these women this disease is terminal (1, 2, 3). According to the data from 2015, in Europe 12-30/100,000 women are affected by cervical cancer. The frequency is higher in poorly developed countries, while it is declining in most of the highly developed countries due to well-organized screening. The incidence of cervical cancer is at the second inglorious place among other malignant diseases affecting women in Montenegro, immediately after breast cancer. According to the available data for 2016, in Montenegro more than 100 women are affected annually, with a terminal outcome in 30-40 of them (2. 3). For comparison, the regional data show that in Croatia 16/100 000 women are affected, while in Serbia 24.3/100 000 women are affected, making Serbia one of the leading countries in Southeastern Europe in the frequency of cervical cancer (2.4). It should be emphasized that there has been an increase in incidence and mortality rate of this disease among the younger population in the recent years (2).

AIM

The aim of our study was to point out the importance of risk factors and to determine the prevalence of the most important risk factors associated with the development of cervical cancer in asymptomatic (general) population.

MATERIALS AND METHODS

A clinical study was conducted at the Department of Obstetrics and Gynecology of the Community Health Center in Rozaje, with the purpose of a timely detection, treatment, and reduction of incidence and mortality rate of cervix cancer in Montenegro, in accordance with the ethical principles of the Declaration of Helsinki and approved by the Ethics Committee of the Faculty of Medicine in Podgorica. The study included 860 patients in the period from January 2017 to January 2018, which covered more than 80% of the targeted population in this municipality over the one year study, according to the National Program for Cervical Cancer Prevention in Montenegro. The subjects were examined for the well-known, long-defined factors and co-factors, which are the main causes of cervical cancer (the number of births, the type of delivery, smoking, the number of children, the use of oral contraceptives, bacterial-viral infections, the time of first sexual intercourse, and the use of an intrauterine device).

Data Analysis

For the analysis of primary data we used descriptive statistical methods and analytical methods. Among the descriptive statistical methods used were the absolute and relative numbers, chi-square test for the analysis of frequency differences and Fisher’s exact probability test. Statistical hypotheses were tested at the level of statistical significance (alpha level) of 0.05. For the purpose of statistical data analysis, SPSS Statistics 22 (SPSS Inc., Chicago, IL, USA) software package was used.

RESULTS

Class 2 Pap smear (PAP II) results were highly prevalent in all age groups, with the incidence of over 95% in most groups. PAP II results were detected in all the subjects belonging to the 22-27 and 58-63 age groups, while the subjects belonging to the 40-45 age group had the lowest incidence of PAP II, amounting to 89% (Table 1).
Table 1.

Characteristics of subjects in relation to Pap II results

Characteristics of subjectsPAP II
NoYes
Total number n (%)17 (2%)843 (98%)
Years of age
16-21 years of age n(%)1 (7.7)12 (92.3)
22-27 years of age n(%)0 (0.0)78 (100.0)
28-33 years of age n(%)2 (1.8)112 (98.2)
34-39 years of age n(%)1 (0.6)166 (99.4)
40-45 years of age n(%)16 (11.3)125 (88.7)
46-51 years of age n(%)4 (3.0)129 (97.0)
52-57 years of age n(%)5 (4.3)112 (95.7)
58-63 years of age n(%)0 (0.0)66 (100.0)
64-69 years of age n(%)1 (3.2)30 (96.8)
Type of delivery
No delivery n(%)0 (0.0)22 (100.0)
Vaginal n(%)29 (4.4)635 (95.6)
Caesarean n(%)1 (0.6)173 (99.4)
Number of children
No children n(%)0 (0.0)22 (100.0)
Up to two n(%)4 (1.6)250 (98.4)
More than two n(%)26 (4.5)558 (95.5)
Women without children
No n(%)30 (3.6)814 (96.4)
Yes n(%)0 (0.0)16 (100.0)
Sexual intercourse before the age of 18
No n(%)15 (1.9)767 (98.1)
Yes n(%)15 (19.2)63 (80.8)
Oral contraception
No n(%)21 (2.6)793 (97.4)
Yes n(%)9 (19.6)37 (80.4)
Intrauterine device
No n(%)27 (3.5)752 (96.5)
Yes n(%)3 (3.7)78 (96.3)
Smoking
No n(%)13 (2.0)629 (98.0)
Yesn(%)17 (7.8)201 (92.2)
Colposcopy
Not done2 (0.2)843 (99.8)
Satisfactory3 (100.0)0 (0.0)
Low-grade12 (100.0)0 (0.0)
Grade of vaginal cleanliness
Group I0 (0.0)1 (100.0)
Group II9 (1.4)655 (98.6)
Group III20 (10.3)174 (89.7)
Group VI1 (100.0)0 (0.0)
The incidence of PAP II results was statistically significantly higher in women with vaginal delivery (p = 0.007). PAP III results were confirmed only in subjects with vaginal delivery with an incidence of 4.4%. PAP III results were statistically significantly higher in subjects with vaginal delivery (p<0.001) (Table 2). PAP III results were statistically significantly more frequent in women with more than two children (p = 0.011). All subjects with positive PAP III results had given birth, and all PAP III results were present only in subjects with vaginal delivery.
Table 2.

Characteristics of subjects in relation to Pap III results

Characteristics of subjectsPAP II
NoYes
Total number n (%)844 (98%)16 (2%)
Years of age
16-21years of age n(%)13 (100.0)0 (0.0)
22-27 years of age n(%)78 (100.0)0 (0.0)
28-33 years of age n(%)112 (98.2)2 (1.8)
34-39 years of age n(%)166 (99.4)1 (0.6)
40-45 years of age n(%)125 (88.7)16 (11.3)
46-51 years of age n(%)129 (97.0)4 (3.0)
52-57 years of age n(%)112 (95.7)5 (4.3)
58-63 years of age n(%)66 (100.0)0 (0.0)
64-69 years of age n(%)30 (96.8)1 (3.2)
Type of delivery
No delivery n(%)22 (100.0)0 (0.0)
Vaginal n(%)635 (95.6)29 (4.4)
Caesarean n(%)174 (100.0)0 (0.0)
Number of children
No children n(%)22 (100.0)0 (0.0)
Up to twon(%)251 (98.8)3 (1.2)
More than two n(%)558 (95.5)26 (4.5)
Women without children
No n(%)815 (96.5)29 (3.4)
Yes n(%)16 (100.0)0 (0.0)
Sexual intercourse before the age of 18
No n(%)768 (98.2)14 (1.8)
Yes n(%)63 (80.8)15 (19.2)
Oral contraception
No n(%)794 (97.5)20 (2.5)
Yes n(%)37 (80.4)9 (19.6)
Intrauterine device
No n(%)753 (96.7)26 (3.3)
Yes n(%)78 (96.3)3 (3.7)
Smoking
No n(%)630 (98.1)12 (1.9)
Yes n(%)201 (92.2)17 (7.8)
Colposcopy
Not done831 (99.9)1 (0.1)
Satisfactory0 (0.0)10 (100.0)
Low-grade0 (0.0)18 (100.0)
Grade of vaginal cleanliness
Group I1 (100.0)0 (0.0)
Group II656 (98.8)8 (1.2)
Group III174 (89.7)20 (10.3)
Group IV0 (0.0)1 (100.0)
The incidence of PAP III results was statistically significantly higher in the 40-45 age group compared to other age groups (p<0.001) (Table 2). PAP II results were statistically significantly more frequent in subjects who did not have sexual intercourse before the age of 18 (p<0.001). The incidence of PAP III results was statistically significantly higher in subjects who had sexual intercouse before the age of 18 (p<0.001). PAP II results were statistically significantly more frequent in subjects that did not use intraoral contraceptives (p<0.001). The incidence of PAP III results was statistically significantly more frequent in subjects who used oral contraceptives (p <0.001). PAP II results were statistically significantly more frequent in non-smoker subjects (p <0.001). PAP II results were statistically significantly more frequent in subjects with grade II vaginal cleanliness compared to subjects with grade III vaginal cleanliness (p <0.001). PAP III results were statistically significantly more frequent in subjects with grade III vaginal cleanliness compared to subjects with grade II vaginal cleanliness (p < 0.001), which again confirms the significance, or rather the role the infection plays in the development of cervical cancer. The incidence of PAP III results were statistically significantly different with respect to the consumption of cigarettes (p <0.001). PAP II findings are statistically significantly more frequent in subjects with grade II vaginal cleanliness compared to subjects with grade III vaginal cleanliness (p <0.001). Two thirds of the purposfully targeted subjects with positive PAP III results had low-grade colposcopy findings, while the findings were satisfactory in 34.5% of the subjects. (Figure 1). The incidence of abnormalities that were confirmed in low-grade colposcopy findings is shown in Figure 2, with two abnormalities confirmed in some of the subjects.
Figure 1.

The distribution of colposcopic findings in subjects with Pap III results

Figure 2.

The distribution of low-grade colposcopic findings in subjects with Pap III results

The most frequent colposcopic abnormalities were punctate lesions (40%), followed by leukoplakia lesions (28%) and AW epithelium (24%). Erythroplakia lesions made up 8% of all colposcopic abnormalities. Biopsy was performed on 25 targeted subjects with positive Class 3 Pap smear results. Histopathological analysis (Hp) was performed in 28 subjects, of which 25 (89.3%) with cervicitis chronica and 3 (10.7%) subjects with a confirmed carcinoma in situ. Microbiological analysis of cervical smear was also performed only in patients with positive PAP III results. Half of the subjects had a heterogeneous group of bacteria, none of which was dominant, while heterogeneous flora with no dominance but with a lot of leukocytes was present in 21% of women. 14% tested positive for Candida albicans while Esherichia Coli was isolated in 11% of subjects. 3.6% of women were diagnosed with Proteus mirabilis. HPV typing was performed in 25 subjects, all with positive PAP III results, and 3 (12%) of those subjects tested positive.

DISCUSSION

It has been determined that HPV infection is the most powerful epidemic factor. This virus is needed, but not sufficient for the development of cervical cancer. The difference in the incidence of PAP results in subjects who did not have sexual intercourse before the age of 18 points to a high incidence of PAP II results in all age groups (over 92%), while PAP III results were present only in the 45-50 age group, with the incidence of 7.7%. 60% of the subjects who had sexual intercourse before the age of 18 tested positive for PAP III, while the highest statistically significant incidence of 50% was recorded in the 45-60 age group compared to other groups (chi-square = 9,195, <0.01). A different study investigated the relationship between cervical cancer and the time of first sexual intercourse using the data on monogamous women from the International Collaboration of Epidemiological Studies on Cervical Cancer. The odds ratio for invasive cervical cancer is approximately proportional to the square of the time of the first sexual intercourse (7). Literature data on the use of oral contraceptives are contradictory. The use of oral contraceptives for more than five years has been associated with an increased risk of cervical cancer, but this risk has disappeared after the adjustment to HPV, smoking and age. Since it is postulated that oral contraceptives act via influencing the folate status (Butterworth et al, 1982; Harper et al, 1994), the possibility of an interaction between the oral contraceptives and the folate status was studied and it was determined that the risk of CIN III was not associated with the use of oral contraceptives in women with high or low folate intake (7). Another study found that taking oral contraceptives barely increases the risk of cervical cancer, if at all, because women who use them are more active, less likely to use condoms and more often undergo PAP tests in order to be prescribed a suitable contraceptive by a gynecologist (8, 18). The role of contraception has been a subject of a huge number of multicenter studies (9). The role of contraception remains controversial, but an increased incidence of unusual histological types in women with a long-term use of contraceptives has been observed (10), which is in accordance with our research results. Tobacco smoking and the development of cervical cancer are positively related. The reason may be found in the direct mutagenic effect of decomposed products of tobacco smoking (cocaine, nicotine), making the risk 2-4 times higher in women who smoke. Women who smoke 15 and more cigarettes a day are at a 2 times higher risk of HPV infection than non-smokers, the incidence higher in women aged between 45 and 50 and at about 37% in women under 35. Women older than 65 make up 10% of patients (7, 14, 15). The highest mortality rate was detected in the group of women over 65 years of age due to the advanced stage of the disease at the time the diagnosis was made, where 50% of subjects smoked tobacco and 50% were non-smokers (11). In subjects who were smokers the incidence of PAP II results was high in all age groups (over 83%), almost 15% higher than in non-smokers of all age groups, while PAP III results had the highest frequency of 16.7% in the 45-60 age group, (12) which coincides with our results. A study conducted at the WHO Collaborative Center at Uppsala University determined that tobacco smoking, alcohol consumption and the use of narcotics were risk factors, but not causative agents. HPV was detected in 66 (6.8%) of 972 women who were admitted for counseling. Among women with confirmed HPV infection, 33 (50%) were smokers, while there were 307 (33.9%) smokers in the group of HPV negative women (13, 16). Plummer et al. published a multicenter study in 2003. By analyzing 8 invasive cancer studies and 2 carcinoma in situ studies, the authors concluded that consistent smokers had an increased risk of cervical cancer and added that planocellular cervical cancer should be added to the list of nicotine-related carcinomas, while additional data would be needed to reach the same conclusion for adenocarcinoma (20). Studies of the relationship between bacterial-viral infections and PAP results conducted so far showed the incidence of infection of 15% for PAP I positive subjects and 33% for PAP III positive subjects. The study showed that the incidence of bacterial vaginosis was statistically significantly higher in patients with precancerous lesions on the cervix or with cervical cancer than in healthy women (14, 19).

CONCLUSION

The results obtained by examining individual risk factors for the disease and premalignant cervical lesions lead to the conclusion that, according to all investigated factors, cervical cancer is most frequent in the 35-50 age group, which does not deviate significantly from the results in other countries in the region. In Serbia, the incidence of the onset of the disease is highest in the 48-52 age group, while in the rest of Europe it is in the 25-44 age group (among the European countries, the lowest incidence was detected in Scandinavia) (17). Tobacco smoking, the use of contraceptives, and the number of births are factors that showed no statistically significant deviations in the studied population compared to other countries in the region, as well as European countries. They have an equal statistical significance in all age groups, as can be seen from the discussion. There was a close association between subjects with bacterial-viral infections and the incidence of PAP abnormalities that were followed by low-grade colposcopy findings in the subjects, especially PAP III in the subjects over the age of 40. In the studied population, PAP III results were statistically significant in patients between the ages of 40 and 45, while the European study showed the incidence of PAP III results of above 33%, but in a slightly younger population (under 30 years of age) with untreated infections. The National Program for Cervical Cancer Prevention in Montenegro did not make adequate progress in the early diagnosis of cervical cancer, which is reflected in an increase in the number of patients, so it is our recommendation to take adequate measures and activities for the proper implementation of the program.
  13 in total

1.  Cervical cancer in the developing world.

Authors:  J Sherris; C Herdman; C Elias
Journal:  West J Med       Date:  2001-10

2.  Passive smoking and cervical cancer risk: a meta-analysis based on 3,230 cases and 2,982 controls.

Authors:  Xian-Tao Zeng; Ping-An Xiong; Fen Wang; Chun-Yi Li; Juan Yao; Yi Guo
Journal:  Asian Pac J Cancer Prev       Date:  2012

Review 3.  Oral contraceptives, human papillomavirus and cervical cancer.

Authors:  Carlo La Vecchia; Stefania Boccia
Journal:  Eur J Cancer Prev       Date:  2014-03       Impact factor: 2.497

4.  How many cervical cancers are prevented by treatment of screen-detected disease in young women?

Authors:  Peter Sasieni; Alejandra Castanon; D Max Parkin
Journal:  Int J Cancer       Date:  2009-01-15       Impact factor: 7.396

5.  Incidence of cervical cancer in Montenegro.

Authors:  B Colaković; V Colaković-Popović
Journal:  Clin Exp Obstet Gynecol       Date:  2008       Impact factor: 0.146

6.  Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study.

Authors:  Kirsten E Jensen; Louise T Thomsen; Sven Schmiedel; Kirsten Frederiksen; Bodil Norrild; Adriaan van den Brule; Thomas Iftner; Susanne K Kjær
Journal:  Sex Transm Infect       Date:  2014-04-12       Impact factor: 3.519

7.  Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys.

Authors:  Salvatore Vaccarella; Rolando Herrero; Peter J F Snijders; Min Dai; Jaiye O Thomas; Nguyen Trong Hieu; Catterina Ferreccio; Elena Matos; Hector Posso; Silvia de Sanjosé; Hai Rim Shin; Sukhon Sukvirach; Eduardo Lazcano-Ponce; Nubia Muñoz; Chris J L M Meijer; Silvia Franceschi
Journal:  Int J Epidemiol       Date:  2008-03-03       Impact factor: 7.196

8.  Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors.

Authors:  Salvatore Vaccarella; Joannie Lortet-Tieulent; Martyn Plummer; Silvia Franceschi; Freddie Bray
Journal:  Eur J Cancer       Date:  2013-06-08       Impact factor: 9.162

9.  10. Cancers attributable to exposure to hormones in the UK in 2010.

Authors:  D M Parkin
Journal:  Br J Cancer       Date:  2011-12-06       Impact factor: 7.640

10.  Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection.

Authors:  L Kjellberg; G Hallmans; A M Ahren; R Johansson; F Bergman; G Wadell; T Angström; J Dillner
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  5 in total

Review 1.  Electrical stimulation on adverse events caused by chemotherapy in patients with cervical cancer: A protocol for a systematic review of randomized controlled trial.

Authors:  Peng-Hui Dou; Dan-Feng Zhang; Cui-Hong Su; Xiao-Li Zhang; Ying-Jie Wu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

2.  Cervical cancer knowledge and screening uptake by marginalized population of women in inner-city Durban, South Africa: Insights into the need for increased health literacy.

Authors:  Jennifer F Ducray; Colette M Kell; Jyotika Basdav; Firoza Haffejee
Journal:  Womens Health (Lond)       Date:  2021 Jan-Dec

3.  Women's perception of cervical cancer pap smear screening.

Authors:  Kristine N Siseho; Beauty Etinosa Omoruyi; Benjamin I Okeleye; Vincent I Okudoh; Hans J Amukugo; Yapo G Aboua
Journal:  Nurs Open       Date:  2022-03-04

4.  Radiological evaluation of metastatic lymph nodes in carcinoma cervix with emphasis on their infiltrative pattern.

Authors:  Ekta Dhamija; Akhil Baby; Neerja Bhatla; Vishnu Prasad Pulappadi; Mukesh Kumar; Sunesh Kumar; Lalit Kumar; Dayanand Sharma
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

5.  HPV molecular detection from urine versus cervical samples: an alternative for HPV screening in indigenous populations.

Authors:  Francisco I Torres-Rojas; Miguel A Mendoza-Catalán; Luz Del C Alarcón-Romero; Isela Parra-Rojas; Sergio Paredes-Solís; Marco A Leyva-Vázquez; Jair E Cortes-Arciniega; Carlos J Bracamontes-Benítez; Berenice Illades-Aguiar
Journal:  PeerJ       Date:  2021-06-17       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.